Healthcare >> CEO Interviews >> November 6, 2000
DR BERND R SEIZINGER, MD, PhD is the President & Chief Executive Officer
of GPC Biotech. He joined GPC Biotech in 1998, having previously held
the post of Executive Vice President and Chief Scientific Officer at
Genome Therapeutics Corporation (Waltham/Boston, USA). While at Genome
Therapeutics, he was instrumental in establishing numerous genomics and
drug discovery collaborations. From 1992 to 1996, Dr Seizinger was Vice
President of Oncology at Bristol-Myers Squibb Pharmaceutical Research
Institute in Princeton, NJ. In parallel, from 1994 through 1996, he also
held the position of Vice President of Corporate and Academic Alliances.
Prior to his corporate career, from 1984 to 1992, Dr Seizinger was at
Harvard Medical School and Massachusetts General Hospital in Boston,
eventually holding the positions of Associate Professor of Neuroscience
at Harvard Medical School and Director of the Molecular Neuro-Oncology
Laboratory at Massachusetts General Hospital. He was awarded his MD from
the Ludwig-Maximilians-University and his PhD from the Max Planck-
Institute for Psychiatry, both in Munich. Dr Seizinger is the recipient
of a number of scientific awards and has authored over one hundred
publications. He retains his visiting professorship at the Department of
Molecular Biology at Princeton University and serves on the Supervisory
Board of Byk Gulden, the pharmaceutical subsidiary of Altana AG, (Bad
Homburg, Germany). Profile
GPC Biotech?
Dr. Seizinger: From its very beginning, GPC Biotech has been following a
dual business model: on the one
